Literature DB >> 21162916

[Malignant lymphoma associated with primary Sjögren's syndrome].

Li Wang1, Yan Zhao, Feng-chun Zhang.   

Abstract

OBJECTIVE: To address the clinical features of malignant lymphoma (ML) occurring in primary Sjögren's syndrome (pSS), understand their similarities and differences and explore their risk factors.
METHODS: Medical records of 17 cases of pSS/ML inpatients admitted to our hospital from January 1980 to August 2010 were systemically reviewed. And 163 cases were randomly selected as controls from 4485 pSS/nML inpatients at our hospital during the same period.
RESULTS: There were 14 females and 3 m ales with the diagnostic age of pSS at (53 ± 13) years old. And the disease duration was (8 ± 9) years. There was no significant difference between two groups in three general aspects (P > 0.05). The gap between pSS and ML was (4 ± 4) years. Several significant differences existed between two groups (P < 0.05) in clinical features and laboratory findings: lymphadenopathy, parothydomegalia and leucopenia. The pathologic categories of ML in pSS/ML included NHL (n = 15) (14 cases of B-cell origin), HL (n = 1) and lymphosarcoma (n = 1).
CONCLUSION: During the course of pSS, the occurrence of such manifestations as lymphadenopathy, parothydomegalia and leucopenia, etc.tends to have a complication of ML with a dominance of NHL. And a worse prognosis is expected.

Entities:  

Mesh:

Year:  2010        PMID: 21162916

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

1.  Primary Sjögren's syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia.

Authors:  Faten Ismail; Amel Mahmoud; Hisham Abdelhaleem; Amro Mamdoh; M Geneidy; Enas Kamal
Journal:  Rheumatol Int       Date:  2012-08-12       Impact factor: 2.631

2.  Ileocecal junction perforation by colonic T-cell lymphoma in a patient with primary Sjögren's syndrome.

Authors:  Xiao-Chuan Liu; Zhi-Wei Jia; Yan Weng; Lian-Jun Yang; Jing Wang; Hao Peng
Journal:  J Int Med Res       Date:  2019-12-25       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.